GenLab has announced a strategic investment in Lymbic AI, a neurotechnology startup specializing in brainwave-based biometric security, highlighting a shared commitment to enhancing digital identity integrity.

Information on the Target

Lymbic AI is a pioneering neurotechnology startup focused on biometric security through brainwave recognition. Its flagship product, Neuroprint, utilizes electroencephalography (EEG) signals—distinct electrical patterns emitted by the brain—to authenticate users without physical contact. This innovative approach aims to address the growing need for secure identity verification in an era increasingly vulnerable to deepfake technology and synthetic fraud.

Neuroprint captures and analyzes ten consecutive EEG samples taken over one second, ensuring that the identity confirmation process is both continuous and highly accurate. With authentication rates exceeding 99.9% for typical use cases, Lymbic AI’s solution offers a reliable alternative to conventional security methods in sensitive sectors such as defense, finance, and healthcare.

Industry Overview in the Target’s Specific Country

The biometric security industry is experiencing rapid growth, particularly in the United States, where security measures are paramount due to increasing cybersecurity threats. With a market